Drug
IPI-145 (duvelisib)
IPI-145 (duvelisib) is a pharmaceutical drug with 3 clinical trials. Historical success rate of 33.3%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(67%)
Phase Distribution
Ph phase_1
3
100%
Phase Distribution
3
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
3(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
33.3%
1 of 3 finished
Non-Completion Rate
66.7%
2 ended early
Currently Active
0
trials recruiting
Total Trials
3
all time
Status Distribution
Completed(1)
Terminated(2)
Detailed Status
Terminated2
Completed1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
0
Success Rate
33.3%
Most Advanced
Phase 1
Trials by Phase
Phase 13 (100.0%)
Trials by Status
terminated267%
completed133%
Recent Activity
0 active trials
Showing 3 of 3
terminatedphase_1
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
NCT02292225
terminatedphase_1
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
NCT01476657
completedphase_1
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
NCT02307461
Clinical Trials (3)
Showing 3 of 3 trials
NCT02292225Phase 1
Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY)
NCT01476657Phase 1
A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies
NCT02307461Phase 1
Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3